Correlation Between CytomX Therapeutics and Oncternal Therapeutics

Can any of the company-specific risk be diversified away by investing in both CytomX Therapeutics and Oncternal Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining CytomX Therapeutics and Oncternal Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between CytomX Therapeutics and Oncternal Therapeutics, you can compare the effects of market volatilities on CytomX Therapeutics and Oncternal Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in CytomX Therapeutics with a short position of Oncternal Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of CytomX Therapeutics and Oncternal Therapeutics.

Diversification Opportunities for CytomX Therapeutics and Oncternal Therapeutics

0.27

Correlation Coefficient

CytomX Therapeutics  Oncternal Therapeutics

Modest diversification

The 3 months correlation between CytomX and Oncternal is 0.27. Overlapping area represents the amount of risk that can be diversified away by holding CytomX Therapeutics and Oncternal Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oncternal Therapeutics and CytomX Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on CytomX Therapeutics are associated (or correlated) with Oncternal Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oncternal Therapeutics has no effect on the direction of CytomX Therapeutics i.e., CytomX Therapeutics and Oncternal Therapeutics go up and down completely randomly.

Pair Corralation between CytomX Therapeutics and Oncternal Therapeutics

Given the investment horizon of 90 days CytomX Therapeutics is expected to generate 0.37 times more return on investment than Oncternal Therapeutics. However, CytomX Therapeutics is 2.71 times less risky than Oncternal Therapeutics. It trades about -0.01 of its potential returns per unit of risk. Oncternal Therapeutics is currently generating about -0.11 per unit of risk. If you would invest  121.00  in CytomX Therapeutics on September 16, 2024 and sell it today you would lose (10.00) from holding CytomX Therapeutics or give up 8.26% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	87.69%
Values	Daily Returns

CytomX Therapeutics  vs.  Oncternal Therapeutics

CytomX Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days CytomX Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong primary indicators, CytomX Therapeutics is not utilizing all of its potentials. The recent stock price disturbance, may contribute to short-term losses for the investors.

Oncternal Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Oncternal Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in January 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with CytomX Therapeutics and Oncternal Therapeutics

The main advantage of trading using opposite CytomX Therapeutics and Oncternal Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if CytomX Therapeutics position performs unexpectedly, Oncternal Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncternal Therapeutics will offset losses from the drop in Oncternal Therapeutics' long position.

The idea behind CytomX Therapeutics and Oncternal Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.